PUBLICATIONS

Items that have been published by the UKCB are listed on this page

THE MANAGEMENT OF GLYCAEMIC CONTROL IN PATIENTS WITH CANCER - updated Sept 2021

Guidance for the diabetes and oncology multidisciplinary teams. Report of a working party on behalf of the UK Chemotherapy Board and Joint British Diabetes Societies for Inpatient Care.

September 2021

CLINICIAN FAQS AND GUIDANCE ON COVID-19 VACCINE FOR PATIENTS RECEIVING SYSTEMIC ANTI-CANCER THERAPY (SACT). VERSION 5.0
Updated on website 24th Sept 2021

This document has been produced in response to questions raised by cancer health care professionals relating to the administration of the Pfizer/BioNTech COVID-19 vaccine and the Oxford University/AstraZeneca COVID-19 vaccine in patients receiving SACT.

PERSONALISED MEDICINE APPROACH FOR FLUOROPYRIMIDINE-BASED THERAPIES

To provide clinical staff with guidance as to which patients should receive a DPD test and then subsequently to provide advice to clinical staff on the outcome of that test.

MEDICATION-RELATED OSTEONECROSIS OF THE JAW: GUIDANCE FOR THE ONCOLOGY MULTI-DISCIPLINARY TEAM

This guidance has been produced by a multi-disciplinary working party on behalf of the UK Chemotherapy Board and endorsed by the Clinical Standards Committee of the Faculty of Dental Surgery of the Royal College of Surgeons of England. It  focuses on all aspects of medication-related osteonecrosis of the jaw (MRONJ) in relation to oncology patients.

ENDORSEMENT POLICY

UK Chemotherapy board endorsement policy to guide professional organisations requesting endorsement for documents, policies, position statements or meetings.

GOOD PRACTICE GUIDELINE FOR IMMUNO-ONCOLOGY MEDICINES

This guideline is designed to give a practical framework for the safe introduction and ongoing use of immunotherapy in existing Systemic Anti-Cancer Therapy (SACT) services.

PROMOTING EARLY IDENTIFICATION OF SYSTEMIC ANTI-CANCER THERAPIES SIDE EFFECTS: TWO APPROACHES – GOOD PRACTICE GUIDELINE

Guidance was produced in response to concerns that patients often delay reporting serious SACT side effects. Two complementary approaches to improve side effect reporting are suggested.

MORBIDITY AND MORTALITY WITHIN 30 DAYS OF SYSTEMIC ANTI-CANCER THERAPY - REVIEW OF CURRENT PRACTICE - STANDARDISED REVIEW PROCESS

The importance of having mortality meetings to review deaths within 30 days of treatment with SACT has been established and most trusts have developed their own system for deciding which cases to discuss. The UK Chemotherapy Board recognised the many current examples of good practice but noted an inconsistency of approach between centres which may limit sharing of learning. It has summarised the key details of the processes currently used and developed a proposed template for an operational policy and pro forma.